|Title:||Methods of treating androgenic alopecia with finasteride [17.beta.-N-mono-substituted-carbamoyl-4-aza-5-.alpha.-androst-1-en-ones]|
|Abstract:||17.beta.-N-monosubstituted-carbamoyl-4-5.alpha.-androst-1-en-3-ones of the formula ##STR1## wherein R.sup.1 is selected from hydrogen, methyl and ethyl and R.sup.2 is a branched chain alkyl of from 3-12 carbons, and R', R", R'" are hydrogen or methyl are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of androgenic alopecia.|
|Inventor(s):||Rasmusson; Gary H. (Watchung, NJ), Reynolds; Glenn F. (Westfield, NJ)|
|Assignee:||Merck & Co., Inc. (Rahway, NJ)|
Patent Claim Types:|
see list of patent claims
|Country||Document Number||Publication Date||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|Australia||626293||Jul 30, 1992|
|European Patent Office||0285382||Oct 05, 1988|
|South Africa||9100676||Feb 24, 1993|
|European Patent Office||0314199||Sep 18, 1991|
|European Patent Office||0271219||Jun 15, 1988|
|This preview shows a limited data set|
Subscribe for full access
Export unavailable in trial.
Subscribe for complete access.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.